Regulation 33 of SEBI LODR ,2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts more than Nifty Microcap 250 and 6.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unjha Formulations reported total income from operations of ₹434.74 lakhs for Q2 FY26, up about 14% from ₹380.66 lakhs in Q2 FY25. The company swung to an operating profit of ₹81.78 lakhs in Q2 FY26, compared to a loss of ₹11.06 lakhs in the same quarter last year, with EPS of ₹1.83 versus a negative ₹0.25. For the half year ended September 2025, total income rose to ₹798.15 lakhs and PAT more than doubled to ₹120.78 lakhs from ₹58.82 lakhs in H1 FY25. Net cash from operating activities was strongly positive at ₹103.99 lakhs, lifting cash balances to ₹160.08 lakhs. The auditor (Jain & Golechha) issued an unqualified limited review report.
The sharp return to profitability, doubling of half-yearly PAT, and strong operating cash flow are positive signals for shareholders, though other equity remains negative (₹134.17 lakhs) reflecting past accumulated losses.